Switch studies in virologically suppressed patients

Switch to LPV/r monotherapy
Switch to LPV/r monotherapy
Original article : Cahn P, EACS 2009; Abs. PS4/3
Last update : 28/03/2014

Dr Anton Pozniak
Chelsea and Westminster Hospital
London, UK

  • LPV/r monotherapy is a potential strategy in virologically suppressed patients on a PI/r-containing regimen

Design (multicenter study in South and North America) :

Primary endpoint :

  • Proportion of patients with HIV-1 RNA < 200 c/mL at Day 360 (ITT analysis)

  • PI/r used at screening: LPV/r = 56% ; SQV/r = 21% ; IDV/r = 21%
  • Outcome at Day 360
    • HIV-1 RNA < 200 c/mL
      • Triple therapy: 96.9% vs LPV/r monotherapy: 97.4%
    • HIV-1 RNA < 50 c/mL
      • Triple therapy: 93.8% vs LPV/r monotherapy: 94.9%
  • Discontinuation: 7 in the triple therapy group vs 2 in the LPV/r group
  • 4 patients on LPV/r monotherapy required reinitiation of 2 NRTIs, all achieving HIV-1 RNA < 50 c/mL
  • Diarrhoea was more frequent in the LPV/r group (3.5% vs 1.1 %)
  • Patients on LPV/r monotherapy had higher LDL cholesterol levels

 

Back to Table of Contents

Copyright AEI 2017 | Links | Contact | Faculty and Disclosure | Terms of use aei